Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Total 13F shares
-
122,375,547
-
Share change
-
+1,057,990
-
Total reported value
-
$2,479,575,024
-
Put/Call ratio
-
48%
-
Price per share
-
$20.26
-
Number of holders
-
195
-
Value change
-
+$23,949,172
-
Number of buys
-
107
-
Number of sells
-
66
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2017
As of 31 Dec 2017,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
195 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,375,547 shares.
The largest 10 holders included
Third Security, LLC, BlackRock Inc., Vanguard Group Inc, IRIDIAN ASSET MANAGEMENT LLC/CT, BB BIOTECH AG, First Eagle Investment Management, LLC, Invesco Ltd., STATE STREET CORP, FMR LLC, and JPMORGAN CHASE & CO.
This page lists
195
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.